Digital Marketing Trends in Rheumatoid Arthritis, 2022 Research Report Featuring AbbVie, Janssen, Eli Lilly, Amgen, UCB, Pfizer, Roche, Sanofi, & Regeneron - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Digital Marketing Trends in Rheumatoid Arthritis" report has been added to ResearchAndMarkets.com's offering.

AbbVie's Humira.com achieved the highest total traffic across RA patient sites in the US, with 7.3 million visitors from February 2021 to January 2022, followed by Pfizer's Xeljanz.com and Amgen's Enbrel.com.

The highest proportion of traffic to branded patient RA websites originated from direct sources, followed by paid. Remicade.com and Simponi.com had the highest proportion of traffic from direct search, followed by Enbrel.com.

For patient branded sites, AbbVie spent the most on DDA for Humira.com at $4.9 million, followed by AbbVie's Rinvoq.com at $3.5 million, and Pfizer's Xeljanz.com at $2.1 million.

For HCP sites, AbbVie's Humirapro.com had the highest number of total visitors, totaling around 190,000 visits from February 2021 to January 2022. The highest proportion of traffic to HCP websites in the US originated from organic and direct sources. Actemrahcp.com had the highest proportion of traffic from organic searches, followed by Remicadehcp.com.

In the US, Genentech and Sanofi were the top companies using corporate social media channels to post RA-related content. AbbVie's branded Complete Medication Tracker app for Humira and Rinvoq had the highest downloads in 2021.

In EUCAN, AbbVie is a leading player with high traffic to its country-specific branded AbbVie Care sites, as well as Janssen with its Bioadvancemember.ca.

In EUCAN, AbbVie's Instagram account in Spain had the highest interaction for RA-related posts. There were few EUCAN mobile apps with notable activity in 2021, with Biogen's Care+ Italia app achieving the most downloads.

Scope

• This report assesses key digital marketing metrics of pharma assets in rheumatoid arthritis (RA), including branded websites for patients and healthcare professionals (HCPs), mobile apps, and social media accounts
• Metrics include website traffic volume, engagement, and source, digital display advertising (DDA), paid search engine optimization (SEO), mobile app downloads, and social media post interaction
• Countries include the US, 4EU (Italy, France, Germany, and Spain), the UK, and Canada (EUCAN)

Reasons to Buy

• Understand the digital marketing competitive landscape in RA, with a view of leading patient and HCP branded assets across different regions
• See what tactics pharma companies are using to drive traffic to their RA branded assets for patient and HCPs, such as DDA and paid SEO
• Understand what sources of website traffic are generating the most visits to these assets, such as paid SEO, social media, or organic searches
• Compare top branded assets for patients by how they address and support different patient needs
• See what pharma social media accounts in RA are the most active and achieving the most engagement
• See leading mobile app offerings in RA from pharma across different regions

Key Topics Covered:

• Executive Summary
• US Patient Branded Websites
• US Hcp Branded Websites
• US Digital Display Advertising and Search Engine Optimization
• US Mobile Apps and Social Media
• Eucan Branded Websites
• Eucan Mobile Apps and Social Media
• Appendix

Companies Mentioned

• AbbVie
• Janssen
• Eli Lilly
• Amgen
• UCB
• Pfizer
• Roche
• Sanofi
• Regeneron

For more information about this report visit https://www.researchandmarkets.com/r/sb65dq